GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS

Completed · Phase 3 · Has a placebo group

Conditions studied: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome

In brief

The GRACE-2 study is a prospective, multi-center, double-blind, randomized controlled trial of the drug GM-CSF vs placebo in children with sepsis-induced multiple organ dysfunction syndrome (MODS) who have immunoparalysis with mild to moderate inflammation.

Key facts

Study ID
NCT05266001
Run by
Nationwide Children's Hospital
People needed
141
Starts
2022-06-14
Expected to finish
2025-09-10
Last updated by the study team
2026-04-09

Who can join

Age: 0 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.